PE20250781A1 - Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso - Google Patents
Composicion farmaceutica y que comprende derivados de difenildiazol metodos de usoInfo
- Publication number
- PE20250781A1 PE20250781A1 PE2024001775A PE2024001775A PE20250781A1 PE 20250781 A1 PE20250781 A1 PE 20250781A1 PE 2024001775 A PE2024001775 A PE 2024001775A PE 2024001775 A PE2024001775 A PE 2024001775A PE 20250781 A1 PE20250781 A1 PE 20250781A1
- Authority
- PE
- Peru
- Prior art keywords
- diphenyldiazole
- pharmaceutical composition
- fatty acid
- polyethylene glycol
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22159408 | 2022-03-01 | ||
| PCT/EP2023/055160 WO2023166045A1 (en) | 2022-03-01 | 2023-03-01 | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250781A1 true PE20250781A1 (es) | 2025-03-14 |
Family
ID=80623476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001775A PE20250781A1 (es) | 2022-03-01 | 2023-03-01 | Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250161273A1 (https=) |
| EP (1) | EP4486340A1 (https=) |
| JP (1) | JP2025508912A (https=) |
| KR (1) | KR20240155237A (https=) |
| CN (1) | CN118715010A (https=) |
| AU (1) | AU2023227368A1 (https=) |
| CA (1) | CA3246018A1 (https=) |
| CL (1) | CL2024002379A1 (https=) |
| IL (1) | IL314952A (https=) |
| MX (1) | MX2024009773A (https=) |
| PE (1) | PE20250781A1 (https=) |
| WO (1) | WO2023166045A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025068949A1 (en) | 2023-09-26 | 2025-04-03 | Teva Pharmaceutical Industries Ltd. | Emrusolmin for use in treating multiple system atrophy |
| KR20250090047A (ko) * | 2023-12-12 | 2025-06-19 | 가천대학교 산학협력단 | 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2687513B1 (en) * | 2008-06-09 | 2020-12-02 | Ludwig-Maximilians-Universität München | Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| KR102671166B1 (ko) * | 2015-12-14 | 2024-05-31 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 3,5-디페닐-디아졸 화합물의 수용성 유도체 |
-
2023
- 2023-03-01 US US18/840,374 patent/US20250161273A1/en active Pending
- 2023-03-01 PE PE2024001775A patent/PE20250781A1/es unknown
- 2023-03-01 WO PCT/EP2023/055160 patent/WO2023166045A1/en not_active Ceased
- 2023-03-01 KR KR1020247029979A patent/KR20240155237A/ko active Pending
- 2023-03-01 JP JP2024550866A patent/JP2025508912A/ja active Pending
- 2023-03-01 CN CN202380024479.XA patent/CN118715010A/zh active Pending
- 2023-03-01 EP EP23707119.6A patent/EP4486340A1/en active Pending
- 2023-03-01 CA CA3246018A patent/CA3246018A1/en active Pending
- 2023-03-01 MX MX2024009773A patent/MX2024009773A/es unknown
- 2023-03-01 AU AU2023227368A patent/AU2023227368A1/en active Pending
- 2023-03-01 IL IL314952A patent/IL314952A/en unknown
-
2024
- 2024-08-08 CL CL2024002379A patent/CL2024002379A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250161273A1 (en) | 2025-05-22 |
| CL2024002379A1 (es) | 2025-01-24 |
| WO2023166045A1 (en) | 2023-09-07 |
| KR20240155237A (ko) | 2024-10-28 |
| EP4486340A1 (en) | 2025-01-08 |
| MX2024009773A (es) | 2024-08-19 |
| IL314952A (en) | 2024-10-01 |
| CA3246018A1 (en) | 2023-09-07 |
| AU2023227368A1 (en) | 2024-07-18 |
| JP2025508912A (ja) | 2025-04-10 |
| CN118715010A (zh) | 2024-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20250781A1 (es) | Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso | |
| PE20231081A1 (es) | Derivados de quinoxalina como farmacos contra el cancer | |
| CO2022004594A2 (es) | Oxinitruro de piridina, método para su preparación y uso de este | |
| PE20220762A1 (es) | Derivados de acido itaconico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable | |
| PE20232051A1 (es) | Compuestos carboxi-benzimidazol moduladores de glp-1r | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| EP2581376A4 (en) | MATRIC ACID / MATRIN DERIVATIVES AND MANUFACTURING METHOD AND USES THEREOF | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| JP2013525286A5 (https=) | ||
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| RU2015120376A (ru) | Новые антибактериальные соединения и их биологическое применение | |
| AR073117A1 (es) | Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios. | |
| PE20241474A1 (es) | Compuestos que contienen heteroatomos y usos de estos | |
| AR133240A1 (es) | Compuestos, composiciones y métodos | |
| AR127431A1 (es) | Compuestos novedosos | |
| AR065419A1 (es) | Metodo para inhibir la proliferacion de celulas tumorales | |
| AR128100A1 (es) | Compuestos para el tratamiento de la pérdida del cabello | |
| AR039027A1 (es) | Compuesto de los acidos 4-[(8-substituido)-6-cromanoil] y 4-[(8-substituido)-croman-6-il-etinil]-benzoico y fenilacetico, composicion farmaceutica que lo comprende y su uso para prepararla | |
| JP2025508912A5 (https=) | ||
| AR128917A1 (es) | Inhibidores de malt-1 de tiazolo[5,4-b]piridina | |
| RU2017137960A (ru) | Применение тиаоксосоединений для уменьшения содержания аро сз | |
| JOP20190282A1 (ar) | مركبات وتركيبات لحث تكوّن الغضاريف | |
| AR035446A1 (es) | Compuestos de benzoilo, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento antiinflamatorio o inmunosupresor | |
| AR133698A1 (es) | COMPUESTOS Y COMPOSICIONES COMO AGENTES DEGRADANTES DE CBP / p300 Y USOS DE ESTOS |